Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Altimmune, Inc.
This extension study will enroll subjects who have completed 12 weeks of treatment in Study ALT-801-105. It is designed to allow for an additional 12 weeks of treatment in order to assess the safety and effects of 24 weeks of treatment with ALT-801 in diabetic and non-diabetic subjects with overweight and obesity and non-alcoholic fatty liver disease (NAFLD).
Age
18–65
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Written informed consent to participate in this extension study, signed prior to the performance of any study procedures
Receipt of 12 weeks of investigational product with completion of the procedures in Study ALT-801-105
Women who are not pregnant or breastfeeding
You may not be if
Development of any of the following conditions at any time during Study ALT-801-105:
1. Type 1 DM and/or insulin-dependent type 2 diabetes mellitus (T2DM), or uncontrolled T2DM requiring rescue therapy in study ALT-801-105
2. History of pancreatitis or hypersensitivity reaction to GLP-1 analogues
Clareo Health | Extension of ALT-801 in Diabetic and Non-Diabetic Overweight and Obese Subjects With (NAFLD)
